Holen Sie sich die Stockscreener-App
4.37
8.58%
-0.41
Schlusskurs vom Vortag:
$4.78
Offen:
$4.79
24-Stunden-Volumen:
371.79K
Relative Volume:
1.00
Marktkapitalisierung:
$170.15M
Einnahmen:
$5.74M
Nettoeinkommen (Verlust:
$-166.12M
KGV:
-1.0931
EPS:
-3.9978
Netto-Cashflow:
$-131.64M
1W Leistung:
-22.93%
1M Leistung:
-36.57%
6M Leistung:
-67.77%
1J Leistung:
-29.29%
1-Tages-Spanne:
$4.345
$4.85
1-Wochen-Bereich:
$4.1092
$5.69
52-Wochen-Spanne:
$4.1092
$16.45
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Firmenname
Entrada Therapeutics Inc
Sektor
Branche
Telefon
857-305-1825
Adresse
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
4.37 | 170.15M | 5.74M | -166.12M | -131.64M | -3.9978 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-04-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-02-11 | Eingeleitet | Guggenheim | Buy |
| 2026-01-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-12-06 | Eingeleitet | ROTH MKM | Buy |
| 2024-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Entrada Therapeutics Inc Aktie (TRDA) Neueste Nachrichten
TRDA 8-K & SEC Filings - Yahoo! Finance Canada
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 - GlobeNewswire Inc.
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study - GlobeNewswire Inc.
Entrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying Opportunity - Seeking Alpha
Coya Therapeutics, Inc. (COYA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance Singapore
TRDA S-8 & SEC Filings - Yahoo! Finance Canada
Responsive Playbooks and the TRDA Inflection - Stock Traders Daily
MPM BioVentures 2014, L.P. Offloads 259,837 Shares of Entrada Therapeutics (NASDAQ: TRDA) at $7.11-$7.41 Each - Kalkine Media
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Australia
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program - The Manila Times
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Australia
Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock - Investing.com
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares - Investing.com
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com India
Entrada therapeutics 10% owner MPM BioVentures sells $1.9M stock By Investing.com - Investing.com Canada
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com Canada
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com UK
MPM funds sell Entrada (TRDA) shares, still hold stakes over 1.7M each - Stock Titan
MPM funds sell 259,837 Entrada Therapeutics (TRDA) shares over 3 days - Stock Titan
Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead By Investing.com - Investing.com South Africa
Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead By Investing.com - Investing.com India
Entrada Therapeutics at cantorfitzgerald healthcare conference: data catalysts ahead By Investing.com - Investing.com Canada
Mpm Bioventures 2018 sells $1.9m in Entrada Therapeutics shares By Investing.com - Investing.com South Africa
MPM BIOVENTURES 2018, L.P. Disposes 86,482 Shares of Entrada Therapeutics Between September 1-3, 2026 - Kalkine Media
Entrada Therapeutics' R&D President Sethuraman Natarajan Forfeits 2,079 Shares at $7.14 Each on September 2, 2026 - Kalkine Media
Entrada Therapeutics CFO Wentworth Kory James Forfeits 1,733 Shares at $7.14 Each (NASDAQ: TRDA) - Kalkine Media
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com South Africa
TRDAEntrada Therapeutics Inc Revenue Breakdown - Finviz
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Canada
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com India
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com Canada
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Nigeria
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com Australia
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics - Investing.com
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares By Investing.com - Investing.com UK
Mpm Bioventures, 10% owner, sells $617k in Entrada Therapeutics By Investing.com - Investing.com UK
Institutional holder sells Entrada (NASDAQ: TRDA) shares over three days - Stock Titan
MPM funds sell Entrada (TRDA) shares without 10b5-1 plan - Stock Titan
Entrada Therapeutics (TRDA) CEO sale is tax-driven, still owns 517,290 shares - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) CFO stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) insider stake - Stock Titan
Automatic tax sale trims Entrada Therapeutics (TRDA) COO holdings - Stock Titan
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Mpm Bioventures 2018 sells $617k Entrada Therapeutics shares - Investing.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Liquidity Mapping Around (TRDA) Price Events - news.stocktradersdaily.com
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Finanzdaten der Entrada Therapeutics Inc-Aktie (TRDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Entrada Therapeutics Inc-Aktie (TRDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 09 '26 |
Sale |
7.13 |
28,837 |
205,608 |
3,885,115 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Sep 09 '26 |
Sale |
7.13 |
28,837 |
205,608 |
3,885,115 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 08 '26 |
Sale |
7.41 |
192,500 |
1,426,425 |
3,913,952 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 04 '26 |
Sale |
7.11 |
38,500 |
273,735 |
4,106,452 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Sep 04 '26 |
Sale |
7.11 |
38,500 |
273,735 |
4,106,452 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Sep 03 '26 |
Sale |
7.17 |
32,263 |
231,326 |
4,144,952 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 03 '26 |
Sale |
7.17 |
32,263 |
231,326 |
4,144,952 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 02 '26 |
Sale |
7.19 |
25,131 |
180,692 |
4,177,215 |
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Sep 02 '26 |
Sale |
7.19 |
25,131 |
180,692 |
4,177,215 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Sep 01 '26 |
Sale |
7.06 |
29,088 |
205,361 |
4,202,346 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):